Galera Therapeutics
Pennsylvania, United States · Healthcare, Health Care · 14 employees
Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
Funding history
- Series seed — $2.9M — Jan 2025
- Series seed — $2.7M — Jan 2025
- Funding Round — $15.0M — Nov 2016
- Funding Round — $37.1M — Oct 2015
Recent signals
- May 11, 2026: SEC 8-K (5.03): On May 11, 2026, Galera Therapeutics, Inc. filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of Delaware, increasing the number of authorized shares of common stock from 200 million to 400 million. Additionally, on May 12, 2026, the company provided its stockholders a right to act by written consent through another amendment. Both amendments were approved at the Annual Meeting of Stockholders held on May 8, 2026, indicating a significant change in corporate structure that enhances capital flexibility and shareholder rights. The strategic implications suggest a proactive approach to business expansion and shareholder engagement.
- Apr 27, 2026: Acquired Galera to merge with Obsidian for $350 million deal
- Apr 14, 2026: Acquired Galera Therapeutics and Obsidian merge to innovate
- Jan 14, 2025: Raised $2.9M in Series seed
- Jan 13, 2025: Raised $2.7M in Series seed
- Nov 28, 2016: Raised $15.0M
- Oct 14, 2015: Raised $37.1M
See plans & pricing → Track Galera Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.